Futuremeds Sp. z o.o.
- Address
- lock Available on a paid plan
Futuremeds Sp. z o.o. - Advanced Clinical Research Center
Futuremeds Sp. z o.o. is a comprehensive clinical research center specializing in cutting-edge Phase 2 and Phase 3 trials across diverse therapeutic areas. The center demonstrates particular expertise in conducting complex multinational studies evaluating novel therapeutic agents and biosimilars, with a strong focus on metabolic, cardiovascular, immunological, and dermatological disorders.
- Metabolic disorders including Type 2 diabetes, NASH/MASH, obesity, hypertriglyceridemia, and weight management interventions
- Cardiovascular and renal conditions: heart failure, chronic kidney disease, hypertension, and atrial fibrillation
- Immunology and rheumatology: psoriatic arthritis, psoriasis, atopic dermatitis, ulcerative colitis, Crohn's disease, systemic lupus erythematosus, and Sjögren's syndrome
- Neurology and rare diseases: Alzheimer's disease, trigeminal neuralgia, migraine, multiple sclerosis, and vitiligo
The facility is equipped to manage sophisticated clinical protocols including cardiovascular outcomes trials, post-authorization safety studies, and long-term extension studies. Futuremeds demonstrates proficiency in evaluating innovative drug classes such as GLP-1 agonists, JAK inhibitors, IL-23 inhibitors, FGF21 analogs, and antisense oligonucleotides. The center's research portfolio includes studies on diabetic retinopathy, HER2-low breast cancer, primary biliary cholangitis, and postmenopausal osteoporosis, reflecting capabilities in both common and specialized disease areas. With experience in decentralized clinical trial methodologies and vaccine research including RSV and influenza prevention, Futuremeds offers comprehensive research services across the full spectrum of modern therapeutic development.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 8 therapeutic areas and 15 of 39 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 7 by active trials.
lock +6 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Futuremeds Sp. z o.o.
lock Showing 1 of 13 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Dose Levels of ESK-001 in Adult Patients with Systemic Lupus Erythematosus | Alumis Inc. | Phase II | Not Recruiting | Oct 2023 | — |
IMP list
lock Showing 1 of 39 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Deucravacitinib | 2 | Unknown | 2023-05-25 | 2024-01-31 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.